Navigation Links
Simcere Pharmaceutical Group Announces its Special Committee's Engagement of Financial Advisor
Date:4/3/2013

NANJING, China, April 3, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that its Special Committee of the Board of Directors (the "Special Committee"), which was formed to consider a proposal by Mr. Jinsheng Ren , New Good Management Limited, Assure Ahead Investments Limited and its affiliates (the "Buyer Group"), pursuant to which the Buyer Group proposes to acquire all of the outstanding ordinary shares of the Company not currently owned by the Buyer Group, and any potential alternative transactions involving the Company, has retained UBS AG and/or its affiliates as its exclusive financial advisor to assist it in its work. No decisions have been made by the Special Committee with respect to the Company's response to the proposed transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857

In the United States:

Cindy Zheng

Brunswick Group LLC

Tel: 1-212-333-3810



In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600



'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
2. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
3. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
5. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
6. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
8. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
9. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
11. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
(Date:1/16/2017)... and PUNE, India , January ... new report published by Allied Market Research, titled, "Sterilization ... Analysis and Industry Forecast, 2014-2022," the global sterilization technologies ... from $5,768 million in 2015, growing at a CAGR ... gas sterilization segment dominated the market in 2015, with ...
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... Maryland (PRWEB) , ... January 16, 2017 , ... ... Thibodeau has been appointed Chief Executive Officer of the medical device company, effective ... Vixiar Chairman Robert Storey. “Kevin has a strong track record in medical ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/14/2017)... , ... January 13, 2017 , ... ... and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type ... Lounge notes that the many health and wellness benefits linked to a Mediterranean ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
Breaking Medicine News(10 mins):